PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Tilray Brands, Inc. (TLRY.TO)
2.000.05 (2.56%)
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-2.12%
Negative revenue growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would investigate if the company is losing market share or facing a declining industry.
21.56%
Gross profit growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 0.00%. Joel Greenblatt would check if cost advantages or brand equity drive this surge.
123.81%
EBIT growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 4.88%. Joel Greenblatt would examine whether a unique competitive edge supports this outperformance.
123.81%
Operating income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 7.09%. Joel Greenblatt would see if unique processes drive exceptional profitability.
645.04%
Net income growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.48%. Joel Greenblatt would check if brand strength or cost advantages fuel this outperformance.
22200.00%
EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.32%. Joel Greenblatt would confirm if consistent earnings expansion underpins these gains.
22200.00%
Diluted EPS growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 5.32%. Joel Greenblatt would confirm if strong net income growth or buybacks drive outperformance.
5.52%
Share growth above Drug Manufacturers - Specialty & Generic median by more than 2x. Jim Chanos would suspect over-dilution or repeated equity raises.
6.15%
Diluted share change of 6.15% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a slight difference in equity issuance policy.
No Data
No Data available this quarter, please select a different quarter.
-170.95%
Negative OCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would ask if accounting or macro issues hamper the firm specifically.
-106.82%
Negative FCF growth while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would see if others in the industry are still generating positive expansions in free cash.
No Data
No Data available this quarter, please select a different quarter.
656.29%
5Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 3.86%. Joel Greenblatt would see if the company’s moat drives rapid mid-term expansion.
17.13%
3Y revenue/share growth exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 10.33%. Joel Greenblatt might see a short-term competitive advantage at play.
-267.86%
Negative 10Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would suspect the firm is failing to keep pace with industry peers.
-478.36%
Negative 5Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman might see a firm-specific issue if peers still expand cash flow.
-28.16%
Negative 3Y OCF/share CAGR while Drug Manufacturers - Specialty & Generic median is 0.00%. Seth Klarman would check whether it’s cyclical or a firm-specific problem.
440.92%
Net income/share CAGR of 440.92% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a marginal edge that can grow if the firm invests wisely.
122.39%
Net income/share CAGR of 122.39% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage that can expand mid-term.
122.65%
3Y net income/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 11.83%. Joel Greenblatt might see a recent surge from market share gains or cost synergy.
6526.78%
Equity/share CAGR of 6526.78% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss might see a modest advantage in net worth accumulation that could matter long term.
522.42%
5Y equity/share CAGR > 1.5x Drug Manufacturers - Specialty & Generic median of 8.10%. Joel Greenblatt sees a possible ROE advantage or fewer share issuances boosting book value.
56.04%
3Y equity/share CAGR of 56.04% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest short-term advantage that could compound if momentum persists.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.73%
AR growth of 5.73% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss checks if the difference points to new credit strategy or stronger sales push.
17.28%
Inventory growth far above Drug Manufacturers - Specialty & Generic median. Jim Chanos suspects major issues in demand forecasting or potential obsolescence risk.
0.97%
We expand assets while Drug Manufacturers - Specialty & Generic is negative. Peter Lynch sees a possible advantage if expansions align with profitable markets or a recovering cycle.
-1.25%
Negative BV/share change while Drug Manufacturers - Specialty & Generic median is -2.86%. Seth Klarman sees a firm-specific weakness if peers accumulate net worth.
-8.37%
Debt is shrinking while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman might see an advantage if growth remains possible.
-68.16%
R&D dropping while Drug Manufacturers - Specialty & Generic median is rising. Seth Klarman wonders if we risk ceding future innovation or if peers overspend.
19.59%
SG&A growth of 19.59% while Drug Manufacturers - Specialty & Generic median is zero. Walter Schloss sees a modest overhead increase needing revenue justification.